RxDoctor Payments Data

Christopher Wong

Optometrist · Manchester, NHNPI 1063158137

Payments from drug & device makers

$1,295in general payments, 2019–2025

Across 47 payments — averaging $27.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$420
  • AbbVie$326
  • Glaukos Corporation$254
  • Alcon$170
  • Thea Pharma Inc.$84
  • Rxsight Inc$24
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$1,295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,295 in reported general payments places this provider in the 65th percentile of 235 optometrist providers in New Hampshire.

See all optometrist providers in New Hampshire

Medicare billing

Part B allowed, 2024
$411,385
Medicare patients
1,597
Services billed
5,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost301$150,226
RocklatanNetarsudil Mesylat/Latanoprost187$84,973
VyzultaLatanoprostene Bunod188$78,247
CombiganBrimonidine Tartrate/Timolol61$29,433
RhopressaNetarsudil Mesylate48$21,465
Dorzolamide-TimololDorzolamide/Timolol/Pf87$19,223
SimbrinzaBrinzolamide/Brimonidine Tart78$18,452
RestasisCyclosporine15$18,268
IyuzehLatanoprost/Pf38$17,248
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol99$17,035
Brimonidine Tartrate540$16,074
Alphagan PBrimonidine Tartrate38$12,338
TafluprostTafluprost/Pf44$9,611
Latanoprost948$9,429
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat516$8,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$326$210,265415 claims
Bausch & Lomb Americas Inc.Vyzulta$420$78,247188 claims
AlconSimbrinza$170$18,45278 claims
Thea Pharma Inc.Iyuzeh$84$17,24838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 235 optometrist providers in New Hampshire.

Other optometrist in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →